Innovation Pharmaceuticals Inc.
IPIXOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$155504
P/E Ratio—
52W High$0.05
52W Low$0.00001
Innovation Pharmaceuticals Inc. (IPIX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IPIX · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 20, 2023EPS Actual
-$0.00
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 20, 2023
After Market Close
IPIX reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2024 | Dec 6, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Nov 19, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Sep 27, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 29, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Feb 12, 2024 | — | — | — | — | — | — |
| — Q4 FY2023 | Nov 20, 2023 | — | -$0.00 | — | — | — | — |
| — Q3 FY2023 | Sep 28, 2023 | — | -$0.00 | — | $-0.00B | — | — |
| — Q2 FY2023 | May 15, 2023 | — | -$0.00 | — | — | — | — |
Q4 FY2024
Dec 6, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 19, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Sep 27, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 29, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Feb 12, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 20, 2023
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Sep 28, 2023
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$-0.00B
Q2 FY2023
May 15, 2023
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 20, 2023 | — | $0.01 | $0.01 | -6.49% |
| — Q3 FY2023 | Sep 28, 2023 | — | $0.01 | $0.01 | -2.17% |
| — Q2 FY2023 | May 15, 2023 | — | $0.02 | $0.02 | +1.71% |
| — Q1 FY2023 | Feb 15, 2023 | — | $0.02 | $0.02 | -3.56% |
| — Q4 FY2022 | Nov 10, 2022 | — | $0.03 | $0.03 | -1.57% |
| — Q3 FY2022 | Sep 28, 2022 | — | $0.04 | $0.04 | +2.82% |
| — Q2 FY2022 | May 13, 2022 | — | $0.03 | $0.03 | -4.00% |
Q4 FY2023-6.49%
Report Date
Nov 20, 2023
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q3 FY2023-2.17%
Report Date
Sep 28, 2023
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q2 FY2023+1.71%
Report Date
May 15, 2023
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q1 FY2023-3.56%
Report Date
Feb 15, 2023
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q4 FY2022-1.57%
Report Date
Nov 10, 2022
EPS Beat/Miss
—
Price Before
$0.03
Price After
$0.03
Q3 FY2022+2.82%
Report Date
Sep 28, 2022
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.04
Q2 FY2022-4.00%
Report Date
May 13, 2022
EPS Beat/Miss
—
Price Before
$0.03
Price After
$0.03
Beat Rate0 / 7 quarters
Largest Move-6.49% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IPIX ends December
Innovation Pharmaceuticals Inc. (IPIX) most recently reported earnings on November 20, 2023 for Q4 FY2023, posting EPS of $-0.00 (in line with the analyst consensus of —). The next IPIX earnings date is expected around September 1, 2026.
Each quarter, investors track IPIX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IPIX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IPIX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IPIX earnings · 4 questionsInnovation Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. IPIX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IPIX historically reports after market close (AMC).
IPIX earnings datewhen is IPIX earningsIPIX next earnings datewhen does IPIX report earningsIPIX earnings calendar
▸ Source: FMP · Innovation Pharmaceuticals Inc. SEC filings · US GAAP · Innovation Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026